Pomerantz announces an investigation into possible breaches of fiduciary duties by the Impax board of directors in connection with the proposed all-stock-merger of Impax with Amneal Pharmaceuticals LLC, in which Impax shareholders will own 25% of the new company's shares and Amneal Holdings members will own 75%.
The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.
Robert S. Willoughby
View original content:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-llp-investigates-claims-that-the-merger-may-not-be-in-the-best-interest-of-investors-of-impax-laboratories-inc–ipxl-300565408.html
SOURCE Pomerantz LLP
Latest posts by Sarah Thompson (see all)
- CytRx Reports 2017 Financial Results - March 19, 2018
- Dolby Laboratories and OPPO Form Strategic Intellectual Property Partnership - March 19, 2018
- Aktiv Solutions Announces Multi-Tiered Ambassador Program in Conjunction With Its #getAktiv Campaign - March 19, 2018